A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 36, Issue 12, 2006, Pages 761-767

  Lee, Jae Jin ^a   Han, Ji Youn ^a   Lee, Dae Ho ^a   Kim, Hyae Young ^a   Chun, Jong Ho ^a   Lee, Hong Gi ^a   Yoon, Seong Min ^a   Lee, Sung Young ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Capecitabine; Docetaxel; Non small cell lung cancer; Second line treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIURETIC AGENT; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; ONDANSETRON; PLATINUM COMPLEX; STEROID; VINCRISTINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; TAXOID;

ABSCESS; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; INFECTION; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RETREATMENT; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; ADENOCARCINOMA; DISEASE FREE SURVIVAL; DOSE RESPONSE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 33947532768     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl106     Document Type: Article

References (24)

1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
2. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. (The TAX 320 Non-Small Cell Lung Cancer Study Group). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
3. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/ 5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001;7:1079-86
4. Kurosumi M, Tabei T, Suemasu K, Inoue K, Kusawake T, Sugamata N, et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000;7:945-8.
5. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-23.
6. Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, et al. A Phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000;83:22-9.
7. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002;20:2616-23.
8. Giatromanolaki A, Koukourakis MI, Comley M, Kaklamanis L, Turley H, Turley H, et al. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol 1997;181:196-9.
9. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. (Xeloda Colorectal Cancer Study Group). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-106.
10. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization 1979.
11. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials 1998;10:1-10.
12. Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
13. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
14. Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002;25:509-12.
15. Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: A phase I/II trial. Cancer Chemother Pharmacol 2003;52:19-24.
16. Chen YM, Shih JF, Lee CS, Chen MC, Lin WC, Tsai CM, et al. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer 2003;39:209-14.
17. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
18. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
19. Jones A, Harris AL. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J Sci Am 1998;4:209-17.
20. Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer 2003;98:1918-24.
21. Hainsworth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-8.
22. Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol 2001;19:3500-5.
23. Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005;55:354-60.
24. Tamila K, Gregory AO, Donn Y, Anterpreet N, Tamara C, Gerard N, et al. Pase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2005;11:1870-6.